AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb. 14. That is almost 6% higher than the prior payout. The company ...
AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based ...
AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...
AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...
Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie (NYSE:ABBV) in the last three months. The table below provides a concise overview of ...
The latest trading session saw AbbVie (ABBV) ending at $211.48, denoting a +1.17% adjustment from its last day's close. This change outpaced the S&P 500's 1.76% loss on the day. At the same time ...
NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume ...
AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and ...